About Vegea
Vegea is a company based in Rovereto (Italy) founded in 2016 by Gianpiero Tessitore, Valentina Longobardo, and Francesco Merlino. Vegea offers products and services including VEGEA® and GrapeSkin®. Vegea operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Rovereto, Italy
- Founders Gianpiero Tessitore, Valentina Longobardo, Francesco Merlino
-
Sectors
RetailHealthcare Chemicals & Materials
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vegea Srl
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$618.61 K (USD), Grant
Aug 31, 2019
-
Investors
European Union
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vegea
Vegea offers a comprehensive portfolio of products and services, including VEGEA® and GrapeSkin®.
Sustainable material from grape waste for fashion and packaging uses
Material derived from wine production waste for eco-friendly applications
Funding Insights of Vegea
Investors in Vegea
Vegea has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Chivas Venture and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startup accelerator
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Vegea
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vegea
Investment portfolio details for Vegea
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vegea
Detailed financials for Vegea
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vegea Comparisons
Peer comparison for Vegea
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vegea
Vegea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Vegea
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vegea
Complete news archive for Vegea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vegea
Vegea was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Vegea is headquartered in Rovereto, Italy. It is registered at Rovereto, Trentino-alto Adige, Italy.
Gianpiero Tessitore is the current CEO of Vegea. They have also founded this company.
Vegea is a biotechnology company that develops biomaterial from wine using bioprocess technology. The material is vegetal leather produced through a specific processing of fibers and vegetal oils contained in grape marc, which is a fully natural raw material consisting of the grape skins, stalks, and seeds obtained from winemaking. The product finds application in fashion design, in order to meet the need for green and animal-free products to be used in these Industries. As of July 2018, the company claims to derive 7 billion Kilograms of grape marc for an annual potential production of 3 billion square meters of Vegea.
Vegea's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Vegea offers VEGEA® and GrapeSkin®.
Vegea has 4 investors. Key investors include European Union, Chivas Venture, EIC Fund, and UniCredit Start Lab.